Back
Arrowhead Pharmaceuticals, Inc. (ARWR)
BiotechnologyARWR · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$84.00
−2.03%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-0.01
ROE
-42.4%
Gross margin
100.0%
Debt/Equity
2.31x
Revenue growth
-86.4%
Arrowhead Pharmaceuticals, Inc. — company intelligence
Earnings surprises
Q2 2026$-0.93 vs $-1.21 est+23.2%
Q1 2026$0.22 vs $0.26 est-14.8%
Q4 2025$-0.18 vs $-0.25 est+26.7%
Q3 2025$-1.26 vs $-1.05 est-20.5%
Insider activity · 90 days
0 buys5 sellsnet -26,065 shares
Lu HongboSell 2,970 · May 12, 2026
Hamilton James CSell 10,000 · Apr 23, 2026
Apel Daniel JosephSell 1,157 · Apr 22, 2026
Recent SEC filings
4 — Insider transaction reportJun 17, 2026
8-K — Material event reportJun 16, 2026
4 — Insider transaction reportMay 14, 2026
Latest news
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target — Benzinga · 1w ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript — SeekingAlpha · 1w ago
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session — Benzinga · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Arrowhead Pharmaceuticals, Inc.
Weekly undervalued picks (like ARWR)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.